Background— The National Cholesterol Education Program (NCEP) recently proposed a
simple definition for metabolic syndrome. Information on the prospective association of this …

Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and
duration of action and have been studied in trials of varying sizes and with different patient …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Background Trials of statin therapy have had conflicting findings on the risk of development
of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of …

Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …

Background Whether intensive control of glucose reduces macrovascular events and all-cause
mortality in individuals with type 2 diabetes mellitus is unclear. We undertook a meta-…

Background Patients with diabetes are at higher risk for death and cardiovascular outcomes
than the general population. We investigated whether the excess risk of death and …

There is intense interest in mechanisms whereby low-grade inflammation could interact with
conventional and novel vascular risk factors to promote the atheromatous lesion. Patients …

Circulation. 2020; 142: 4–6. DOI: 10.1161/CIRCULATIONAHA. 120.047659 July 7, 2020 5
certain ethnicities, eg, Asians. 1 Asians often display lower cardiorespiratory fitness and carry …

Background— There is uncertainty about the association between circulating concentrations
of adiponectin and coronary heart disease (CHD) risk. We report new data from a …